Shopping Cart
Remove All
Your shopping cart is currently empty
Teplizumab (MGA-031) is a humanized monoclonal antibody targeting CD3 that slows the loss of beta cell function and is used to treat type 1 diabetes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $579 | In Stock | In Stock | |
| 10 mg | $928 | - | In Stock | |
| 25 mg | $1,370 | - | In Stock | |
| 50 mg | $1,850 | - | In Stock |
| Description | Teplizumab (MGA-031) is a humanized monoclonal antibody targeting CD3 that slows the loss of beta cell function and is used to treat type 1 diabetes. |
| In vitro | Teplizumab induces human CD8+ T-cell proliferation (10 ng/mL-10 μg/mL, 5 days)[3]. Teplizumab increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs) after 6 days[2]. |
| In vivo | In NSG mice, Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablates the treatment effects of the drug on graft survival[3]. |
| Synonyms | PRV-031, MGA-031 |
| Molecular Weight | 145.79 kDa |
| Cas No. | 876387-05-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.